RT Journal Article
T1 A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma
A1 Lelpo, Benedetto
A1 Caruso, Riccardo
A1 Duran, Hipolito
A1 Diaz, Eduardo
A1 Fabra, Isabel
A1 Malavé, Luis
A1 Ferri, Valentina
A1 Alvarez, Rafael
A1 Cubillo, Antonio
A1 Plaza Hernández, José Carlos
A1 Lazzaro, Sara
A1 Kalivaci, Denis
A1 Quijano, Yolanda
A1 Vicente, Emilio
AB Introduction Neoadjuvant treatment has been reported to prolong survival in patients with potentially resectable pancreatic adenocarcinoma (PA). However, there are currently limited clinical results available using nab-paclitaxel and gemcitabine in PA. This paper compares the oncological results of patients affected by potentially resectable PA who underwent surgery first (SF) versus surgery following neoadjuvant treatment (NAT). Methods This is an observational, comparative study whereby data were abstracted from a prospective database of patients affected by PA from 2007 to 2016. Results We included a total of 81 patients (36 SF and 45 NAT) which resulted in being preoperatively similar. Among the NAT patients, treatment was well tolerated and the resection rate was 68.8% (31/45 patients). There was a trend towards a higher R1 resection rate in the SF group compared with the NAT (13.8% vs 3.2%; p = 0.1). Median overall survival in the resected NAT group was higher (30.6 vs 22.1 months; p = 0.04). In the borderline resectable group, overall survival was found to be four times higher compared with SF (43.6 versus 13.5 months; p = 0.001). Conclusions These data suggest that neoadjuvant treatment with gemcitabine/nab-paclitaxel is a safe and effective option for potentially resectable PA compared with the SF approach.
PB Elsevier
YR 2017
FD 2017-08-21
LK https://hdl.handle.net/20.500.14352/117569
UL https://hdl.handle.net/20.500.14352/117569
LA eng
NO Ielpo, B., Caruso, R., Duran, H., Diaz, E., Fabra, I., Malavé, L., Ferri, V., Alvarez, R., Cubillo, A., Plaza, C., Lazzaro, S., Kalivaci, D., Quijano, Y., & Vicente, E. (2017). A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Surgical Oncology, 26(4), 402-410. https://doi.org/10.1016/j.suronc.2017.08.003
DS Docta Complutense
RD 4 abr 2025